Allegro Diagnostics (Boston) has completed a $4 million Series A financing round led by Kodiak Venture Partners and joined by Catalyst Health Ventures and Boston University. Founded in 2006, Allegro is a molecular diagnostics company focused on developing and commercializing products based on gene expression technology developed by Jerome Brody, M.D., and Avrum Spira, M.D., at the Boston University School of Medicine. Brody was recently appointed chief scientific officer of the company.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

April 2008 - Table of Contents

DTTR April 2008 (full PDF issue)

JAMA Study Sends Chill Through IVD Market

Immucor Bets on Blood Genotyping

Third Wave Sees Clinical Revenue Grow 25% in '07

NEJM Study Probes Pharmacogenomics of Warfarin Metabolism

PerkinElmer Acquires Pediatrix’s Newborn Screening Lab

New Bioimaging System Promises Improved HER2 Testing

Ikonisys Boosts Automated FISH Platform with New Reference Lab

Quidel RSV Test Gets CLIA Waiver

Abbott to Co-Develop Pharmacogenomic Test for Lung Cancer Drug

Quest Diagnostics Signs Onto Google Health EHR

ACLA Presses SACGHS for Clarification on Genetic Testing Oversight

Beckman Coulter Launches High-Volume Testing System

IVD Stocks Fall 7%; Inverness Plummets 33%

Lung Cancer-Focused Allegro Diagnostics Raises $4 Million